Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 09:52 am Purchase | 2025-03-31 | 13G | Savara Inc. SVRA | Frazier Life Sciences Public Fund, L.P. | 11,462,301 6.600% | 2,801,922 (+32.35%) | Filing History |
| 2025-05-15 09:44 am Purchase | 2025-03-31 | 13G | Erasca, Inc. ERAS | Frazier Life Sciences Public Fund, L.P. | 22,575,851 8.000% | 6,359,635 (+39.22%) | Filing History |
| 2025-05-15 09:42 am Sale | 2025-03-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC | Frazier Life Sciences Public Fund, L.P. | 1,410,193 2.000% | -2,732,662 (-65.96%) | Filing History |
| 2025-05-15 09:39 am Purchase | 2025-03-31 | 13G | Palvella Therapeutics, Inc. PVLA | Frazier Life Sciences Public Fund, L.P. | 690,012 6.300% | 114,120 (+19.82%) | Filing History |
| 2025-05-13 4:22 pm Purchase | 2025-05-09 | 13D | Phathom Pharmaceuticals, Inc. PHAT | Frazier Life Sciences Public Fund, L.P. | 14,429,990 19.900% | 1,641,280 (+12.83%) | Filing History |
| 2025-05-05 09:43 am Purchase | 2025-04-28 | 13G | Jade Biosciences, Inc. JBIO | Frazier Life Sciences Public Fund, L.P. | 1,772,116 5.500% | 1,772,116 (New Position) | Filing History |
| 2025-04-29 09:59 am Purchase | 2025-04-25 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 4,451,339 10.200% | 322,339 (+7.81%) | Filing History |
| 2025-04-29 09:58 am Purchase | 2025-03-31 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 4,129,000 9.400% | 935,100 (+29.28%) | Filing History |
| 2025-04-04 12:39 pm Purchase | 2025-04-01 | 13G | Mereo BioPharma Group plc MREO | Frazier Life Sciences Public Fund, L.P. | 40,349,315 5.100% | 40,349,315 (New Position) | Filing History |
| 2025-02-14 11:27 am Sale | 2025-01-31 | 13G | AnaptysBio, Inc. ANAB | Frazier Life Sciences Public Fund, L.P. | 463,241 1.500% | -1,192,054 (-72.01%) | Filing History |
| 2025-02-14 11:25 am Sale | 2024-12-31 | 13G | AnaptysBio, Inc. ANAB | Frazier Life Sciences Public Fund, L.P. | 1,655,295 5.400% | -261,896 (-13.66%) | Filing History |
| 2025-02-14 11:22 am Sale | 2024-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN | Frazier Life Sciences Public Fund, L.P. | 1,176,735 2.000% | -2,384,909 (-66.96%) | Filing History |
| 2025-02-14 11:21 am Purchase | 2024-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 10,664,774 11.900% | 3,283,684 (+44.49%) | Filing History |
| 2025-02-14 11:11 am Sale | 2024-12-31 | 13G | Puma Biotechnology, Inc. PBYI | Frazier Life Sciences Public Fund, L.P. | 0 0.000% | -2,631,713 (Position Closed) | Filing History |
| 2025-02-14 11:07 am Unchanged | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Frazier Life Sciences Public Fund, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-02-10 10:55 am Purchase | 2025-02-03 | 13G | Maze Therapeutics, Inc. MAZE | Frazier Life Sciences Public Fund, L.P. | 3,193,900 7.300% | 3,193,900 (New Position) | Filing History |
| 2025-01-08 3:04 pm Purchase | 2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA | Frazier Life Sciences Public Fund, L.P. | 575,892 5.100% | 575,892 (New Position) | Filing History |
| 2024-11-27 11:01 am Purchase | 2024-11-20 | 13G | Savara Inc. SVRA | Frazier Life Sciences Public Fund, L.P. | 8,660,379 5.000% | 8,660,379 (New Position) | Filing History |
| 2024-11-20 10:44 am Purchase | 2024-11-14 | 13G | MacroGenics, Inc. MGNX | Frazier Life Sciences Public Fund, L.P. | 3,175,665 5.100% | 3,175,665 (New Position) | Filing History |
| 2024-11-07 2:34 pm Purchase | 2024-11-05 | 13D | KalVista Pharmaceuticals, Inc. KALV | Frazier Life Sciences Public Fund, L.P. | 4,887,867 10.000% | 1,200,000 (+32.54%) | Filing History |